mRNA Flu Vaccine Meets Primary End Point Among Older Adults
Moderna’s mRNA-1010 flu vaccine shows promising efficacy, especially for older adults, addressing the urgent need for better influenza prevention.
Advancing Pericarditis Care: The Evolving Role of IL-1 Inhibition and Pharmacist-Cardiologist Collaboration
Experts discussed the promising future of pericarditis treatment.
How Cuts to Federal Health Agencies Fuel Chronic and Infectious Disease Crises
Funding cuts to public health agencies threaten to worsen chronic diseases and ignite infectious disease outbreaks, straining health care systems…
FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency
The new formulation contains little immunoglobulin A, reducing possible risks associated with infusion in patients with primary immunodeficiency.
FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma
Y-90 resin microspheres offer a new option for liver cancer patients for the treatment of unresectable hepatocellular carcinoma.
Sebetralstat Becomes First and Only FDA-Approved Oral, On-Demand Treatment for HAE
Sebetralstat becomes the first FDA-approved oral treatment for hereditary angioedema (HAE), offering rapid relief for patients experiencing acute attacks.
Building a Sustainable Pharmacogenomics Program: A Pharmacist’s Perspective at Ochsner Health
Serena Mitaly, PharmD, outlines how Ochsner Health is building a sustainable pharmacogenomics program by integrating clinical decision support tools into…
Efepoetin Alfa Noninferior to Mircera When Correcting Anemia, Maintaining Hemoglobin in CKD
Patients with chronic kidney disease (CKD) receiving efepoetin alfa demonstrated a response rate of about 75.6%.
Study: High Long-Term Exposure to Fine Particulate Air Pollution is Associated With Diffuse Myocardial Fibrosis
The data emphasize the idea that there are no safe exposure limits as well as the need for guidelines.
Sunvozertinib Approved by FDA as Oral Treatment of NSCLC With EGFR Exon 20 Insertion Mutations
Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth…